Renewal Bio develops synthetic embryo models derived from pluripotent stem cells to study early human development. The company utilizes advanced stem cell biology to generate in vitro models that mimic post-implantation stages of embryogenesis. This platform aims to advance understanding of human biology and developmental processes.
Funding
Funding not disclosed
Founders
Product
Problem
Studying early human development is challenging due to ethical and practical limitations in accessing and observing embryos. This restricts research into the causes of early pregnancy loss, congenital disabilities, and the development of new reproductive technologies.
Solution
Renewal Bio is creating viable human embryo models from naïve embryonic stem cells using artificial wombs and advanced stem-cell technologies. These models allow researchers to study the critical processes of early human development in a controlled, laboratory setting, without the need for naturally derived embryos. By replicating the conditions of the early post-implantation period, Renewal Bio's technology offers a platform for investigating the mechanisms underlying embryogenesis, identifying potential therapeutic targets, and improving our understanding of reproductive health. The resulting insights can accelerate the development of new treatments for infertility, genetic disorders, and other developmental abnormalities.
Target Audience
The primary audience includes researchers in developmental biology, reproductive medicine, and stem cell research, as well as pharmaceutical companies and biotechnology firms focused on developing new therapies for reproductive and developmental disorders.
Features
- Generation of complete human day 14 post-implantation embryo models from naïve embryonic stem cells.
- Ex utero culture system mimicking the uterine environment to support embryo model development.
- Stem cell engineering techniques to control and direct embryo model differentiation.